Show simple item record

Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas

dc.contributor.authorTerada, Keith Y.en_US
dc.contributor.authorJohnson, Terri L.en_US
dc.contributor.authorHopkins, Michael P.en_US
dc.contributor.authorRoberts, James A.en_US
dc.date.accessioned2006-04-07T20:54:07Z
dc.date.available2006-04-07T20:54:07Z
dc.date.issued1989-02en_US
dc.identifier.citationTerada, Keith Y., Johnson, Terri L., Hopkins, Michael, Roberts, James A. (1989/02)."Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas." Gynecologic Oncology 32(2): 228-232. <http://hdl.handle.net/2027.42/28069>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6WG6-4GWTBRM-H/2/78c499dcc033a34f4779bc5985e2fc53en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/28069
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2535999&dopt=citationen_US
dc.description.abstractOver a 27-year period there were 15 patients treated at the University of Michigan Medical center for carcinosarcomas or mixed mesodermal tumors of the ovary. Overall median survival was 11 months. Median survival was 4 months in patients with carcinosarcomas and 13 months in patients with mixed mesodermal tumors (P = 0.066). Patients with a chondrosarcomatous element had a significantly longer median survival than patients with mixed mesodermal tumors lacking cartilaginous differentiation (P = 0.031). The presence of a rhabdomyosarcomatous element did not affect survival. The size of the primary tumor, presence of ascites, FIGO stage, and degree of initial resection (optimal versus suboptimal) did not affect survival. There was no difference in survival between patients receiving postoperative chemotherapy and patients undergoing postoperative irradiation.en_US
dc.format.extent5309205 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleClinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomasen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelOphthalmologyen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelObstetrics and Gynecologyen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Obstetrics and Gynecology and Department of Pathology, University of Michigan School of Medicine, USAen_US
dc.contributor.affiliationumDepartment of Obstetrics and Gynecology and Department of Pathology, University of Michigan School of Medicine, USAen_US
dc.contributor.affiliationumDepartment of Obstetrics and Gynecology and Department of Pathology, University of Michigan School of Medicine, USAen_US
dc.contributor.affiliationumDepartment of Obstetrics and Gynecology and Department of Pathology, University of Michigan School of Medicine, USAen_US
dc.identifier.pmid2535999en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/28069/1/0000512.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/S0090-8258(89)80038-1en_US
dc.identifier.sourceGynecologic Oncologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.